- A Biomarker is a
substance used as an indicator of a biologic state. It is a
characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention.
- Biomarkers
validated by genetic and molecular biology methods can be classified
into three types. 1. Type 0 - Natural history markers 2. Type 1 - Drug
activity markers and 3. Type II - Surrogate markers.
- In medicine, a
biomarker can be a substance whose detection indicates a particular
disease state (for example, the presence of an antibody may indicate an
infection). More specifically, a "biomarker" indicates a change in
expression or state of a protein that correlates with the risk or
progression of a disease, or with the susceptibility of the disease to a
given treatment.
- The use of
biomarkers in BioPharma R&D and diagnostics will enable more
precise, predictive and preventive clinical care. Biomarker-enabled
R&D is evolving into a new discipline with a strong patient
focus
- Molecular biological
markers, or biomarkers, are natural products that can be traced to a
particular biological origin. They are powerful tools that can be used
to trace diseases, drugs and environmental contaminants in modern
systems
- Biomarker can also
be used to indicate exposure to various environmental substances in
epidemiology and toxicology. In these cases, the biomarker may be the
external substance itself (e.g. asbestos particles or NNK from tobacco),
or a variant of the external substance processed by the body (a
metabolite).
- The biomarker
discovery for applications in drug discovery, preclinical studies of
drug development and diagnostics research applications was the largest
and accounted for nearly 48 per cent of the total market in
2007.
- Escalating costs and
lengthy clinical trials are major concerns for researchers attempting to
boost productivity and efficiency in the field of drug discovery.
- Biomarkers are
emerging as the solution to these problems with their ability to reduce
drug development costs and time.
- Growth in the
global biomarkers industry is mainly driven by factors such as
increasing diagnostic applications of biomarkers, increasing R&D funding
for pharma and biotech companies, increasing number of CROs and low cost
of clinical trials in developing countries, the high prevalence of
cancer, and new initiatives for research
-
The biomarkers can be
used for the prognosis and predicting the natural course of a tumor.
They can also help doctors decide which patients are likely to respond
to a given drug and at what dosage it might be most effective
- According to
reputed Market research firms, the global biomarkers market is estimated
to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a
CAGR of 13.8% from 2016 to 2021
|
General
- Biomarker
- Cardiac
Biomarkers
- About
biomarkers
Product
- Expanding The
Frontiers Of Double Stranded DNA Sizing Accuracy
- Explore
Technology
- Imgenex
Product Lines
- Max
biochip
- leading-edge
technology, tools, and service for genetic analysis
Technology
- Available
Technology
- Biomarkers
Technologies
- Cell Cycle in
Cancer
- Decode
Genetics
-
- HDVY
Technology
-
- Proteome
Technology
Report
- Biomarker For
PTSD And Why PTSD Is So Difficult To Treat
- Biomarker May
Be An Early Predictor Of Advanced Breast Cancer
-
- Early Results
from Alzheimer’s Neuroimaging Biomarker Project Show Promise for Faster
Study of Therapies
- Clinical Data
Achieves Validation of Genetic Biomarker for Determining Risk of
Clozapine Induced Agranulocytosis
- System Wide
Peripheral Biomarker Discovery
- Proceedings of a
Joint U.S. Food and Drug Administration
Project
- A Method for
Biomarker Validation and Biomarker-Based Dose Response: A Case Study
with a Bayesian Network Model for Benzene
- Cancer
Biomarkers
- Quantitative
Proteomics
- Integration of
Biomarker Method Validation & Qualification
- Biomarkers At
Eurofins Medinet
- Accelerating the
Drug Development Pipeline
Patent
- Biomarkers For
ALS
- Prostate
Cancer Biomarkers
- Biomarker
Detection In Circulating Cells.
- Biomarkers For
Alzheimer's Disease
- Method For
Detecting Biomarkers
- Implantable
Biomarkers & Method Of Use
- Biomarkers For
Detecting Ovarian Cancer
- Process For
Preparation Of A Biomarkers specification
- Biomarkers
Sensing
- Serum
Biomarkers For Chags Disease
- Osteoarthritis
Biomarkers & Uses Thereof
|
Guidelines
- Guidelines for
the collection and processing of serum- and EDTA-plasma samples
- Guidelines for the
next 10 years of proteomics
Application &
Functions
- Proteomics and
Biomarkers
- Blood Pressure as an
Example of a Biomarker That Functions as a Surrogate
- Biomarkers in
Clinical Development
- Biomarkers as
indicators of environmental and biological sources
- The use of
biomarkers in barramundi to monitor contaminants in estuaries of
tropical North Queensland
- Evaluation of nasal
biomarkers after allergen challenge
- The Evolution
Role Of Biomarkers
- Fluorescence
spectroscopy as a biomarker in a cell culture and in a nonhuman primate
model for ovarian cancer chemopreventive agents
- Using
Biomarkers to Collect Health Data
Consultants
- Consultant
From Park City
- Experts in
biomarker
- Consultant
From Durham
- Consultant
From Australia
- Consultant
From Chicago
Company
Profile
- Company In
Canada
- Company In
Germantown
- Company In
Phoenix
- Company In
Cambridge
- Company In
Boston
- Company In
Wilmington
- Company In
United Kingdom
- Company In
Waltham
- Company In
UK
- Company In
US
- Company In
North America
- Company In
Japan
- Company In San
diego
- Company In
United Kingdom
- Company In
USA
Market
- The Biomarker
Market
- Bio Markers
Current Perspective & Future Prospectus
- Biomarker market
predicted to 'explode'
- Biomarkers
& Drug Discovery
- Strategic
Analysis of Biomarkers in Clinical Trials
- Biomarkers Market Could Hit more than $1 Billion in Revenues
Analysis
- Cardiac
Biomarker Assays
- Early clinical
evaluation for molecularly targeted anticancer agents based on biomarker
analysis
- A Comprehensive
Biomarker Discovery and Analysis
- Drawbacks of
recist criteria for tumor response and biomarker analysis
- Serum Biomarker
Chip
- Multi Layer
Micro Fluid Devices for Amino Acid Biomarker
- Biomarker Modulation
in a Nonhuman Rhesus Primate Model for Ovarian Cancer
Order the CD ROM
Today |